Research

Energy balance

Final proof of efficacy for incretin therapies on primary clinical liver outcomes may come from large database analyses.

Future studies should focus on analyzing large datasets to confirm the efficacy of incretin therapies for NAFLD.

LimitedQualifiesmedium confidence
Final proof of their efficacy on primary clinical liver outcomes might be also derived from the analysis of large databases of National Healthcare Systems or Insurance companies.
Lucia Brodosi et al. · Expert Opinion on Pharmacotherapy · 2023

Why this rating

The claim is based on expert opinion regarding future research needs.

Source

Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes

Lucia Brodosi et al. · Expert Opinion on Pharmacotherapy · 2023

DOI 10.1080/14656566.2023.2208746

reviewCited 7×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →